Chronic lymphocytic leukemia (CLL) cells could be undetectable by flow cytometry or polymerase chain reaction after sequential treatment with fludarabine and Campath-1H. Concern has been raised regarding the ability to mobilize sufficient peripheral blood progenitor cells (PBPCs) for autografting after purine analogues, and there are few data about PBPC collection after Campath-1H. In all, 16 CLL patients responding to sequential chemo-immunotherapy entered the study. In 10, mobilization regimen consisted of granulocyte colony-stimulating factor (G-CSF) 5-10 μg/kg/die. Patients failing mobilization or not achieving the target of 2.5 × 106 CD34+ cells/kg underwent a second attempt using intermediate-dose (ID) Ara-C, 800 mg/m2 every 12 h for six doses + G-CSF. PBPC collection after G-CSF alone was successful in two out of 10 patients. An adequate number of CD34+ cells were collected after ID Ara-C + G-CSF in eight patients failing the mobilization with G-CSF alone and in five out of six who did not receive G-CSF before. Greater yields of PBPCs were collected with Ara-C + G-CSF compared with G-CSF alone (13.8 vs 3.3). The extrahematologic toxicity was manageable. In conclusion, PBPC collection is feasible in CLL patients treated with sequential therapy including fludarabine and Campath-1H. Excellent yields were obtained in 92.8% of patients primed with ID Ara-C + G-CSF.

Montillo, M., Tedeschi, A., Rossi, V., Cairoli, R., Pungolino, E., Intropido, L., et al. (2004). Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. LEUKEMIA, 18(1), 57-62 [10.1038/sj.leu.2403190].

Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H

Cairoli R;
2004

Abstract

Chronic lymphocytic leukemia (CLL) cells could be undetectable by flow cytometry or polymerase chain reaction after sequential treatment with fludarabine and Campath-1H. Concern has been raised regarding the ability to mobilize sufficient peripheral blood progenitor cells (PBPCs) for autografting after purine analogues, and there are few data about PBPC collection after Campath-1H. In all, 16 CLL patients responding to sequential chemo-immunotherapy entered the study. In 10, mobilization regimen consisted of granulocyte colony-stimulating factor (G-CSF) 5-10 μg/kg/die. Patients failing mobilization or not achieving the target of 2.5 × 106 CD34+ cells/kg underwent a second attempt using intermediate-dose (ID) Ara-C, 800 mg/m2 every 12 h for six doses + G-CSF. PBPC collection after G-CSF alone was successful in two out of 10 patients. An adequate number of CD34+ cells were collected after ID Ara-C + G-CSF in eight patients failing the mobilization with G-CSF alone and in five out of six who did not receive G-CSF before. Greater yields of PBPCs were collected with Ara-C + G-CSF compared with G-CSF alone (13.8 vs 3.3). The extrahematologic toxicity was manageable. In conclusion, PBPC collection is feasible in CLL patients treated with sequential therapy including fludarabine and Campath-1H. Excellent yields were obtained in 92.8% of patients primed with ID Ara-C + G-CSF.
Articolo in rivista - Articolo scientifico
Ara-C; Campath-1H; Chronic lymphocytic leukemia; Fludarabine;
English
2004
18
1
57
62
reserved
Montillo, M., Tedeschi, A., Rossi, V., Cairoli, R., Pungolino, E., Intropido, L., et al. (2004). Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. LEUKEMIA, 18(1), 57-62 [10.1038/sj.leu.2403190].
File in questo prodotto:
File Dimensione Formato  
Montillo-2004-Leukemia-VoR.pdf

Solo gestori archivio

Descrizione: Original Article
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Tutti i diritti riservati
Dimensione 118.71 kB
Formato Adobe PDF
118.71 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/408748
Citazioni
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 39
Social impact